The Week in Review: US-based SciClone Buys NovaMed of Shanghai

SciClone Pharma of the US acquired Shanghai-based NovaMed Pharma for $105 million, combining two companies that register and distribute western drugs in China; Jiangbo Pharma signed a LOI to acquire Shandong Xinkangqi Medical Co., a wholesale drug distributor; Morningside Ventures of Hong Kong participated in the $19.25 million second funding round of California startup Aduro BioTech; Neuralstem partnered with BaYi Brain Hospital in Beijing on a stem cell treatment for stroke; Kinex Pharma of the US out-licensed China rights for its lead cancer molecule to Hanmi Pharma of South Korea; and Shanghai Pharma and Pfizer signed a MOU to explore a broad range of mutual projects in China. More details…. Stock Symbols: (NSDQ: SCLN) (NSDQ: JGBO) (AMEX: CUR) (SHA: 601607) (NYSE: PFE) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});